Evidence-based·Last reviewed May 30, 2026·How we grade evidence

Eicosapentaenoic Acid

Fatty-acidBest with a meal

Useful mainly for adults with high triglycerides or high cardiovascular risk who need high-dose omega-3 under medical supervision.

Quick decision guide

May help most

Adults with high triglycerides or high cardiovascular risk who need high-dose omega-3 under medical supervision

Common dosing range

250–500 mg/day (general); 2–4 g/day (hypertriglyceridemia)

When to expect effects

Weeks for triglyceride lowering; months to years for cardiovascular event reduction

Watch out for

At high doses (>3 g/day), increases bleeding time; coordinate with anticoagulant therapy

What is it

Eicosapentaenoic acid (EPA) is a long-chain omega-3 polyunsaturated fatty acid (20:5 n-3) found primarily in fatty fish and algae. It is one of the two main omega-3s in fish oil along with DHA.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have hypertriglyceridemia needing more than dietary management
You have high cardiovascular risk and qualify for high-dose EPA therapy (REDUCE-IT criteria)
You have treatment-resistant depression and want an evidence-based adjunct

Probably skip if…

You expect cardiovascular benefit from low-dose general supplements without underlying risk factors
You are on anticoagulants without informing your prescriber
You are about to have surgery

Evidence at a glance

hypertriglyceridemia

Strong Evidence
Effect
20–50% reduction in triglycerides at 2–4 g/day
Best fit
Adults with triglycerides >500 mg/dL or elevated-risk patients with >200 mg/dL
Time
4–8 weeks

cardiovascular event reduction in high-risk patients

Good Evidence
Effect
25% relative risk reduction in major adverse cardiovascular events (REDUCE-IT)
Best fit
Adults on statins with elevated triglycerides and established cardiovascular disease or diabetes
Time
Years

depression adjunct

Good Evidence
Effect
Modest symptom reduction; EPA appears more effective than DHA for depression
Best fit
Adults with major depressive disorder not fully responding to antidepressants
Time
4–8 weeks

Evidence for 3 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

hypertriglyceridemia

Biomarker support
Strong Evidence

EPA and DHA at 2–4 g/day reduce serum triglycerides by 20–50%, a well-replicated pharmacologic effect across numerous RCTs and meta-analyses. Prescription EPA+DHA (Lovaza) and pure EPA (Vascepa/icosapent ethyl) are FDA-approved for severe hypertriglyceridemia. The mechanism involves reduced hepatic VLDL secretion. Note this is a biomarker (triglyceride) reduction, not a proven endpoint on its own.

Effect size
20–50% reduction in triglycerides at 2–4 g/day
Time to effect
4–8 weeks
Best fit
Adults with triglycerides >500 mg/dL or elevated-risk patients with >200 mg/dL
Less likely
People with normal triglycerides

Bottom line: High-dose EPA reliably lowers triglycerides; this is a well-established biomarker effect backed by multiple meta-analyses.

SourceBhatt et al., 2019 — PubMedLu et al., 2025 — PubMed

cardiovascular event reduction in high-risk patients

Disease adjunct
Good Evidence

The REDUCE-IT trial demonstrated a 25% relative reduction in major adverse cardiovascular events with icosapent ethyl (4 g/day pure EPA) versus placebo in patients on statins with elevated triglycerides. The STRENGTH trial using EPA+DHA in a different formulation was neutral, raising questions about whether the benefit is EPA-specific, dose-specific, or related to the mineral oil control used in REDUCE-IT. The evidence supports EPA at high dose in the appropriate high-risk population.

Effect size
25% relative risk reduction in major adverse cardiovascular events (REDUCE-IT)
Time to effect
Years
Best fit
Adults on statins with elevated triglycerides and established cardiovascular disease or diabetes
Less likely
General population without established risk factors

Bottom line: Pure high-dose EPA reduces cardiovascular events in high-risk statin-treated patients; this is a prescription-level intervention.

Evidence is mixed

REDUCE-IT strongly positive for icosapent ethyl; STRENGTH neutral for EPA+DHA; whether pure EPA versus the mineral oil placebo accounts for the difference remains debated.

SourceNicholls et al., 2020 — PMC· conflictingSayah et al., 2024 — PMC· conflicting
SourceNicholls et al., 2020 — PMCSayah et al., 2024 — PMC

depression adjunct

Disease adjunct
Good Evidence

Meta-analyses of RCTs consistently report that EPA-dominant omega-3 supplementation modestly reduces depression scores as an adjunct to antidepressants, with EPA being more efficacious than DHA for this indication. Effect sizes are modest (SMD ~0.3–0.5). Studies in people with MDD show clearest benefit; effects in non-clinical low mood are less consistent.

Effect size
Modest symptom reduction; EPA appears more effective than DHA for depression
Time to effect
4–8 weeks
Best fit
Adults with major depressive disorder not fully responding to antidepressants
Less likely
People with mild situational low mood or without clinical depression

Bottom line: EPA-dominant omega-3 supplementation modestly reduces depression symptoms as an adjunct, particularly in clinical MDD.

Evidence is mixed

Most meta-analyses favor EPA over DHA; however, some analyses show publication bias and heterogeneity, moderating confidence in the effect size.

SourceLiao et al., 2019 — PMC· conflictingKelaiditis et al., 2023 — PubMed· conflicting
SourceLiao et al., 2019 — PMCKelaiditis et al., 2023 — PubMed

How it works

EPA incorporates into cell membrane phospholipids, partly displacing arachidonic acid. It is the substrate for series-3 prostaglandins, series-5 leukotrienes, and the specialized pro-resolving mediators (resolvins of the E series), which actively resolve inflammation. EPA lowers triglycerides by reducing hepatic VLDL secretion, decreases platelet aggregation, and modulates vascular tone. Higher doses (>2 g/day) are needed for cardiovascular endpoints than for general intake.

How to take it

1. Typical dose
250–500 mg EPA+DHA/day for general use; 2–4 g/day for hypertriglyceridemia
2. Higher studied dose
4 g/day EPA ethyl ester (icosapent ethyl) in REDUCE-IT
3. Timing
With a fat-containing meal for best absorption
4. With food
With food; splitting morning and evening reduces fishy reflux
5. Split dosing
Split larger doses AM and PM to reduce GI side effects
6. How long to try
Ongoing for cardiovascular or lipid indications; 8–12 weeks for depression adjunct trial

What to track

Triglycerides (lab)
Bleeding tendency or bruising
Fishy aftertaste and GI tolerance
Mood if using for depression

3 commercial forms

Compare the main delivery options and what they’re best suited for.

Triglyceride form

Often re-esterified after concentration; preferred by some clinicians.

Closest to dietary form; well absorbed.

Ethyl ester

Most concentrated formulations and icosapent ethyl use this form.

Slightly lower absorption when taken without fat.

Algae-derived EPA

Allergen- and contaminant-friendly alternative.

Vegan source; usually lower EPA content per capsule.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Fishy aftertaste or burpingMild GI upsetLoose stools at high doses

Serious risks

  • Increased bleeding time at >3 g/day; clinically relevant mainly with anticoagulant co-use

Who should avoid it

  • Pre-surgery patients (discontinue 1–2 weeks before)
  • Fish or shellfish allergy (algae oil is an alternative)

Pregnancy & breastfeeding

Low-dose EPA+DHA is recommended in pregnancy for fetal brain development; high doses (>3 g/day) should be medically supervised.

Interactions

warfarinModerate

Additive effect on bleeding time; INR monitoring warranted

other anticoagulants (rivaroxaban, apixaban)Moderate

May increase bleeding risk at high EPA doses

aspirin / clopidogrelMinor

Additive antiplatelet effect; generally clinically manageable but flag before surgery

Food sources

Salmon (3 oz cooked)

Amount
~0.6-1.0 g EPA
%DV
—

Sardines (3 oz)

Amount
~0.4-0.5 g EPA
%DV
—

Mackerel (3 oz)

Amount
~0.4-0.7 g EPA
%DV
—

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

EPA and DHA amounts listed separately in mg
Triglyceride vs. ethyl ester form declared
IFOS or similar third-party purity certification
Enteric coating if fishy reflux is a concern

Be skeptical of…

Universal heart protection at any dose
Replaces statin therapy
Cures depression

Frequently asked questions

Is EPA better than DHA?⌄

Different functions. EPA is the stronger anti-inflammatory and triglyceride-lowering omega-3. DHA is more structural in brain and retina.

How much EPA do I need?⌄

250-500 mg/day combined EPA+DHA for general health; 2-4 g/day for triglyceride or cardiovascular indications.

References by claim

hypertriglyceridemia

Bhatt et al., 2019 — PubMed (2019) link

Lu et al., 2025 — PubMed (2025) link

cardiovascular event reduction in high-risk patients

Nicholls et al., 2020 — PMC (2020) link

Sayah et al., 2024 — PMC (2024) link

depression adjunct

Liao et al., 2019 — PMC (2019) link

Kelaiditis et al., 2023 — PubMed (2023) link

Track Eicosapentaenoic Acid with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.